PEDRO PIEDRA to Treatment Outcome
This is a "connection" page, showing publications PEDRO PIEDRA has written about Treatment Outcome.
Connection Strength
0.150
-
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003 Jul 28; 21(24):3479-82.
Score: 0.017
-
Severe Coronavirus Bronchiolitis in the Pre-COVID-19 Era. Pediatrics. 2020 09; 146(3).
Score: 0.013
-
Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for bronchiolitis. Eur Respir J. 2016 11; 48(5):1329-1339.
Score: 0.010
-
Anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease: a protocol for a double-blinded randomised controlled trial. BMJ Open. 2016 09 16; 6(9):e012060.
Score: 0.010
-
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
Score: 0.010
-
Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
Score: 0.010
-
Post-bronchiolitis Use of Asthma Medication: A Prospective 1-year Follow-up Study. Pediatr Infect Dis J. 2016 Apr; 35(4):363-8.
Score: 0.010
-
Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries. Pediatr Infect Dis J. 2015 Oct; 34(10):1086-92.
Score: 0.010
-
Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis. Pediatr Int. 2015 Oct; 57(5):1031-4.
Score: 0.010
-
Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
Score: 0.009
-
Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
Score: 0.009
-
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
Score: 0.009
-
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
Score: 0.008
-
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007 Nov 19; 25(47):8010-20.
Score: 0.006
-
Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998 Nov; 27(5):1194-200.
Score: 0.003
-
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14; 338(20):1405-12.
Score: 0.003
-
High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994 Oct; 125(4):635-41.
Score: 0.002